Pediatric Infectious Disease

Register      Login

VOLUME 5 , ISSUE 3 ( July-September, 2023 ) > List of Articles


“Prevention of Group B Streptococcus by Vaccination,” Will It Transform Maternal and Neonatal Health?

Keyur D Mahajan

Keywords : Antenatal immunization, Group B Streptococcus, Immunization against group B Streptococcus, Intrapartum antibiotic prophylaxis

Citation Information : Mahajan KD. “Prevention of Group B Streptococcus by Vaccination,” Will It Transform Maternal and Neonatal Health?. Pediatr Inf Dis 2023; 5 (3):84-89.

DOI: 10.5005/jp-journals-10081-1399

License: CC BY-NC 4.0

Published Online: 29-09-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Objective: Group B Streptococcus (GBS) is a leading cause of sepsis, leading to neonatal mortality and morbidity all over the world. Intrapartum antibiotic prophylaxis is the current main modality for the prevention of perinatal transmission of GBS infection. We want to discuss whether antenatal vaccination is an intervention that can help to reduce the GBS burden and improve maternal and neonatal health. Conclusion: The GBS vaccine given during pregnancy is undoubtedly the key to lowering newborn mortality, but we must exercise extreme caution while using it. More study is required to fill in the knowledge gaps and better understand the numerous components of prenatal immunization for improving both mother and baby's health.

  1. Seale AC, Bianchi-Jassir F, Russell NJ, et al. Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis 2017;65(Suppl 2):S200–S219. DOI: 10.1093/cid/cix664
  2. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012;379(9815):547–556. DOI: 10.1016/s0140-6736(11)61651-6
  3. Sigaúque B, Kobayashi M, Vubil D, et al. Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique 2001-2015. PLoS One 2018;13(1):e0191193. DOI: 10.1371/journal.pone.0191193
  4. Venkatesan P. Defeating meningitis by 2030: the WHO roadmap. Lancet Infect Dis 2021;21(12):1635. DOI: 10.1016/S1473-3099(21)00712-X
  5. Principles and Practice of Pediatric Infectious Diseases. 5th edition. Elsevier Health Sciences; 2018.
  6. al. PAe. Lancefield-classification of streptococcus. In: Peter Altmeyer HD, Herbert Neumann, Horst Przuntek, Guido Günther Heinrich Gerken, Sören G. Gatermann, editor. ALTMEYERS ENCYCLOPEDIA2023.
  7. Gaurav K, Marianne CC, Elizabeth M, et al. Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis. Lancet Infect Dis 2016;16(9):1076–1084. DOI: 10.1016/S1473-3099(16)30055-X
  8. (CDC) CfDCaP. Group B Strep (GBS) Fast Facts.,who%20develop%20GBS%20disease%20die.
  9. Giersing BK, Modjarrad K, Kaslow DC, et al. Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015. Vaccine 2016;34(26):2865–2869. DOI: 10.1016/j.vaccine.2016.02.078
  10. Gonçalves BP, Procter SR, Paul P, et al. Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden. Lancet Glob Health 2022;10(6):e807–e819. DOI: 10.1016/s2214-109x(22)00093-6
  11. WHO, Immunization VaB. Group B Streptococcus. Vaccine: full value vaccine assessment. 3 November 2021.
  12. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep 2010;59(Rr-10):1–36.
  13. Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect 2014;68(Suppl 1):S24–S32. DOI: 10.1016/j.jinf.2013.09.011
  14. Prevention of group B streptococcal early-onset disease in newborns: ACOG Committee Opinion, Number 797. Obstet Gynecol 2020;135(2):e51–e72. DOI: 10.1097/aog.0000000000003668
  15. Vekemans J, Moorthy V, Friede M, et al. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine 2019;37(50):7391–7393. DOI: 10.1016/j.vaccine.2017.09.087
  16. Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet 2015;385(9965):362–370. DOI: 10.1016/s0140-6736(14)60236-1
  17. Campbell H, Gupta S, Dolan GP, et al. Review of vaccination in pregnancy to prevent pertussis in early infancy. J Med Microbiol 2018;67(10):1426–1456. DOI: 10.1099/jmm.0.000829
  18. Baxter R, Bartlett J, Fireman B, et al. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics 2017;139(5):e20164091. DOI: 10.1542/peds.2016-4091
  19. Ferrieri P, Flores AE. Surface protein expression in group B streptococcal invasive isolates. Adv Exp Med Biol 1997;418:635–637. DOI: 10.1007/978-1-4899-1825-3_148
  20. Slotved HC, Kong F, Lambertsen L, et al. Serotype IX, a proposed new streptococcus agalactiae serotype. J Clin Microbiol 2007;45(9):2929–2936. DOI: 10.1128/jcm.00117-07
  21. Madrid L, Seale AC, Kohli-Lynch M, et al. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65(Suppl 2):S160–S172. DOI: 10.1093/cid/cix656
  22. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976;294(14):753–756. DOI: 10.1056/nejm197604012941404
  23. Wessels MR, Paoletti LC, Kasper DL, et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B streptococcus. J Clin Invest 1990;86(5):1428–1433. DOI: 10.1172/jci114858
  24. Lagergard T, Shiloach J, Robbins JB, et al. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun 1990;58(3):687–694. DOI: 10.1128/iai.58.3.687-694.1990
  25. Paoletti LC, Kasper DL, Michon F, et al. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B streptococcus. J Biol Chem 1990;265(30):18278–18283.
  26. Paoletti LC, Wessels MR, Michon F, et al. Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1992;60(10):4009–4014. DOI: 10.1128/iai.60.10.4009-4014.1992
  27. Seib KL, Zhao X, Rappuoli R. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin Microbiol Infect 2012;18(Suppl 5):109–116. DOI: 10.1111/j.1469-0691.2012.03939.x
  28. Swamy GK, Metz TD, Edwards KM, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: results from a randomized placebo-controlled phase II trial. Vaccine 2020;38(44):6930–6940. DOI: 10.1016/j.vaccine.2020.08.056
  29. Madhi SA, Cutland CL, Jose L, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis 2016;16(8):923–934. DOI: 10.1016/s1473-3099(16)00152-3
  30. Absalon J, Segall N, Block SL, et al. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect Dis 2021;21(2):263–274. DOI: 10.1016/s1473-3099(20)30478-3
  31. Pfizer CG. Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Nonpregnant Women and Pregnant Women and Their Infants. 2023. Accessed March 22, 2023. Available from:
  32. Leroux-Roels G, Bebia Z, Maes C, et al. Safety and immunogenicity of a second dose of an investigational maternal trivalent group B streptococcus vaccine in nonpregnant women 4-6 years after a first dose: results from a phase 2 trial. Clin Infect Dis 2020;70(12):2570–2579. DOI: 10.1093/cid/ciz737
  33. Schutze MP, Leclerc C, Jolivet M, et al. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 1985;135(4):2319–2322.
  34. Maione D, Margarit I, Rinaudo CD, et al. Identification of a universal group B streptococcus vaccine by multiple genome screen. Science 2005;309(5731):148–150. DOI: 10.1126/science.1109869
  35. Lauer P, Rinaudo CD, Soriani M, et al. Genome analysis reveals pili in group B streptococcus. Science 2005;309(5731):105. DOI: 10.1126/science.1111563
  36. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287(5459):1816–1820. DOI: 10.1126/science.287.5459.1816
  37. Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009;199(1):108–115. DOI: 10.1086/595564
  38. Abu-Raya B, Kollmann TR, Marchant A, et al. The immune system of HIV-exposed uninfected infants. Front Immunol 2016;7:383. DOI: 10.3389/fimmu.2016.00383
  39. Dechavanne C, Cottrell G, Garcia A, et al. Placental malaria: decreased transfer of maternal antibodies directed to plasmodium falciparum and impact on the incidence of febrile infections in infants. PLoS One 2015;10(12):e0145464. DOI: 10.1371/journal.pone.0145464
  40. Okoko BJ, Wesumperuma LH, Ota MO, et al. The influence of placental malaria infection and maternal hypergammaglobulinemia on transplacental transfer of antibodies and IgG subclasses in a rural West African population. J Infect Dis 2001;184(5):627-632. DOI: 10.1086/322808
  41. Oster G, Edelsberg J, Hennegan K, et al. Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective? Vaccine 2014;32(37):4778–4785. DOI: 10.1016/j.vaccine.2014.06.003
  42. Kim SY, Russell LB, Park J, et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine 2014;32(17):1954–1963. DOI: 10.1016/j.vaccine.2014.01.062
  43. Russell LB, Kim SY, Cosgriff B, et al. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa. Vaccine 2017;35(49 Pt B):6905–6914. DOi: 10.1016/j.vaccine.2017.07.108
  44. Ghia C, Rambhad G. Disease burden due to group B streptococcus in the Indian population and the need for a vaccine—a narrative review. Ther Adv Infect Dis 2021;8:20499361211045253. DOI: 10.1177/20499361211045253
  45. Zakariya BP, Bhat V, Harish BN, et al. Neonatal sepsis in a tertiary care hospital in South India: bacteriological profile and antibiotic sensitivity pattern. Indian J Pediatr 2011;78(4):413–417. DOI: 10.1007/s12098-010-0314-8
  46. Marwah P, Chawla D, Chander J, et al. Bacteriological profile of neonatal sepsis in a tertiary-care hospital of Northern India. Indian Pediatr 2015;52(2):158–159.
  47. Bhat YR, Lewis LE, K EV. Bacterial isolates of early-onset neonatal sepsis and their antibiotic susceptibility pattern between 1998 and 2004: an audit from a center in India. Ital J Pediatr 2011;37:32. DOI :10.1186/1824-7288-37-32
  48. Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health 2016;4(10):e752–e760. DOI: 10.1016/s2214-109x(16)30148-6
  49. Pavan Kumar DV, Mohan J, Rakesh PS, et al. Bacteriological profile of neonatal sepsis in a secondary care hospital in rural Tamil Nadu, Southern India. J Family Med Prim Care 2017;6(4):735–738. DOI: 10.4103/jfmpc.jfmpc_66_17
  50. Recommendations for Collection and Culture of Clinical Specimens from Pregnant Women for Group B Streptococcus Minnesota Department of Health 2003.
  51. Davanzo J, Dogo H, Grammich CA. Demographic Trends, Policy Influences, and Economic Effects in China and India Through 2025. 2011.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.